Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Prospective, Multicenter Study Assessing the Contribution and Tolerance of a Multi-targeted Microbiotherapy in Addition to Venlafaxine, After Failure of a First-line Antidepressant Treatment in Depressed Patients

NCT05280015 is registered in ClinicalTrials.gov with Centre Hospitalier Universitaire de Besancon as lead sponsor.

NCT NCT05280015
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05280015 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Prospective, Multicenter Study Assessing the Contribution and Tolerance of a Multi-targeted Microbiotherapy in Addition to Venlafaxine, After Failure of a First-line Antidepressant Treatment in Depressed Patients
Lead sponsor
Centre Hospitalier Universitaire de Besancon
Phase
Phase 2
Overall status
Unknown status
Start date
June 8, 2022
Completion date
December 31, 2024
Enrollment
92 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

depression, depressive disorder, depressive disorder, major